The closing price of Dare Bioscience Inc (NASDAQ: DARE) was $0.50 for the day, up 16.37% from the previous closing price of $0.43. In other words, the price has increased by $+0.0704 from its previous closing price. On the day, 616545 shares were traded.
Ratios:
Our analysis of DARE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.85 and its Current Ratio is at 0.85.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DARE now has a Market Capitalization of 49.38M and an Enterprise Value of 35.68M. For the stock, the TTM Price-to-Sale (P/S) ratio is 49.33. Its current Enterprise Value per Revenue stands at 35.68 whereas that against EBITDA is -0.85.
Stock Price History:
Over the past 52 weeks, DARE has reached a high of $1.15, while it has fallen to a 52-week low of $0.27. The 50-Day Moving Average of the stock is 0.3453, while the 200-Day Moving Average is calculated to be 0.5796.
Shares Statistics:
DARE traded an average of 660.86K shares per day over the past three months and 771.36k shares per day over the past ten days. A total of 98.56M shares are outstanding, with a floating share count of 96.84M. Insiders hold about 1.75% of the company’s shares, while institutions hold 6.70% stake in the company. Shares short for DARE as of Jan 31, 2024 were 560.92k with a Short Ratio of 0.85, compared to 869.8k on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 0.57% and a Short% of Float of 0.58%.
Earnings Estimates
The firm’s stock currently is rated by 5 analysts. On average, analysts expect EPS of -$0.1 for the current quarter, with a high estimate of -$0.06 and a low estimate of -$0.19, while EPS last year was -$0.19. The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.06 and low estimates of -$0.07.
Analysts are recommending an EPS of between -$0.34 and -$0.48 for the fiscal current year, implying an average EPS of -$0.38. EPS for the following year is -$0.19, with 5 analysts recommending between -$0.09 and -$0.27.
